4 completed, 4 unknown, 2 recruiting, 1 active not recruiting. 12 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 4, Unknown 4, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow folfirinox: new trials by email Literature Review of folfirinox trials Research Report on folfirinox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC FOLFIRINOX or gemcitabine-nab-paclitaxel - Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma | Phase 3 | Recruiting | Sahlgrenska University Hospital | 432 | 2023-10-18 | 2024-12-03 |
| NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Folfirinox - Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy | Phase 3 | Recruiting | Seoul National University Hospital | 609 | 2023-04-01 | 2024-11-27 |
| Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Folfirinox and Stereotactic Body Radiotherapy - Pancreatic Adenocarcinoma, Pancreatic Cancer Resectable | Phase 2 / Phase 3 | Unknown | Instituto de investigación e innovación biomédica de Cádiz | 116 | 2022-04-15 | 2022-08-09 |
| Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer Folfirinox - Metastatic Pancreas Cancer | Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 184 | 2021-04-22 | 2021-05-24 |
| Brazilian Total Neoadjuvant Therapy Trial Folfirinox - Colorectal Neoplasms | Phase 3 | Unknown | Hospital Israelita Albert Einstein | 150 | 2020-02-20 | 2023-10-11 |
| Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX - Pancreatic Cancer Non-resectable | Phase 3 | Completed | Kyntra Bio | 284 | 2019-05-10 | 2024-11-05 |
| Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas CPI 613, mFolfirinox, Folfirinox - Pancreatic Cancer Metastatic | Phase 3 | Completed | Cornerstone Pharmaceuticals | 528 | 2018-11-09 | 2023-01-03 |
| Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas FOLFIRINOX + CRT - Cancer of Pancreas | Phase 2 / Phase 3 | Unknown | Assiut University | 1 | 2014-10-01 | 2014-12-08 |
| Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation - Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 3 | Terminated | NewLink Genetics Corporation | 302 | 2013-05-01 | 2020-05-28 |
| Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy Induction chemotherapy with gemcitabine or FOLFIRINOX, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine - Pancreatic Cancer | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 830 | 2013-04-04 | 2024-04-11 |
| Intensified Chemotherapy in CRC After Resection of Liver Metastases FOLFIRI, FOLFOX-4, FOLFIRI-HD - Colorectal Cancer, Liver Metastases | Phase 2 / Phase 3 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 124 | 2004-04-01 | 2026-02-05 |
Pancreatic Neoplasms (5) · Colorectal Neoplasms (3) · Rectal Neoplasms (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assiut University (1) · Cornerstone Pharmaceuticals (1) · Hospital Israelita Albert Einstein (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Instituto de investigación e innovación biomédica de Cádiz (1) · Kyntra Bio (1) · NewLink Genetics Corporation (1) · Sahlgrenska University Hospital (1) · Seoul National University Hospital (1) · UNICANCER (1) · University of Erlangen-Nürnberg Medical School (1)
France (4) · Germany (3) · South Korea (3) · United States (3) · Belgium (2) · Israel (2) · Spain (2) · Sweden (2) · Austria (1) · Brazil (1) · Canada (1) · China (1) · Egypt (1) · Italy (1) · Netherlands (1)
Diogo Gomes, MD (1) · Elena Rangelova, PhD (1) · Philip A Philip, MD, PhD, FRCP (1) · Rainer Fietkau, MD (1) · Wooil Kwon (1)
PMID 23955585, PMID 31512497, PMID 31640628, PMID 33630475, PMID 37678921, PMID 39088774, PMID 40802908
2009 (1)